Enhanced urinary bladder, liver and colon carcinogenesis in zucker diabetic fatty rats in a multiorgan carcinogenesis bioassay: Evidence for mechanisms involving activation of PI3Kk signaling and impairment of p53 on urinary bladder carcinogenesis

Journal of Toxicologic Pathology

Volumn 24, Issue 1, 2011, Pages 25-36

  Ishii, Naomi ^a   Wei, Min ^a   Kakehashi, Anna ^a   Doi, Kenichiro ^a   Yamano, Shotaro ^a   Inaba, Masaaki ^a   Wanibuchi, Hideki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder carcinogenesis; P53; PI3K; Type 2 diabetes mellitus

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ADIPONECTIN; BIS(2 HYDROXYPROPYL)NITROSAMINE; CARCINOGEN; CYCLINE; DIETHYLNITROSAMINE; GLUCOSE; INSULIN; LEPTIN; MESSENGER RNA; METHYLNITROSOUREA; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLADDER CARCINOGENESIS; CANCER SUSCEPTIBILITY; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE LOCATION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; LIVER CARCINOGENESIS; MALE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SIGNAL TRANSDUCTION; ZUCKER DIABETIC FATTY RAT;

EID: 79955402736     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.24.25     Document Type: Article

References (32)

1. Kasper DL, Brouwaid E, Fauci AS, Hauser SL, Longo DL, and Jameson JL. HARRISON'S PRINCIPLES OF Internal Medicine, Vol. 2005.
2. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 47: 87-95. 2010.[Medline] [CrossRef]
3. Larsson SC, Orsini N, Brismar K, and Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 49: 2819-2823. 2006. [Medline] [CrossRef]
4. Terai K, Sakamoto K, Goto M, Matsuda M, Kasamaki S, Shinmura K, Takita N, and Kamano T. Greater development of 1,2-dimethylhydrazine-induced colon cancer in a rat model of type 2 diabetes mellitus. J Int Med Res. 34: 385-389. 2006. [Medline]
5. Yoshizawa N, Yamaguchi H, Yamamoto M, Shimizu N, Furihata C, Tatematsu M, Seto Y, and Kaminishi M. Gastric carcinogenesis by N-Methyl-N-nitrosourea is enhanced in db/db diabetic mice. Cancer Sci. 100: 1180-1185. 2009. [Medline] [CrossRef]
6. Cocca C, Gutierrez A, Nunez M, Croci M, Martin G, Cricco G, Rivera E, and Bergoc R. Suppression of mammary gland tumorigenesis in diabetic rats. Cancer Detect Prev. 27: 37-46. 2003. [Medline] [CrossRef]
7. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 6: 164-179. 1995. [Medline] [CrossRef]
8. Clark JB, Palmer CJ, and Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med. 173: 68-75. 1983. [Medline]
9. Friedman JE, de Vente JE, Peterson RG, and Dohm GL. Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa). Am J Physiol. 261: E782-E788. 1991. [Medline]
10. Sturis J, Pugh WL, Tang J, Ostrega DM, Polonsky JS, and Polonsky KS. Alterations in pulsatile insulin secretion in the Zucker diabetic fatty rat. Am J Physiol. 267: E250- E259. 1994. [Medline]
11. Fukushima S, Hagiwara A, Hirose M, Yamaguchi S, Ti-wawech D, and Ito N. Modifying effects of various chemicals on preneoplastic and neoplastic lesion development in a wide-spectrum organ carcinogenesis model using F344 rats. Jpn J Cancer Res. 82: 642-649. 1991. [Medline]
12. Doi K, Wanibuchi H, Salim EI, Shen J, Wei M, Mitsuhashi M, Kudoh S, Hirata K, and Fukushima S. Revised rat multi-organ carcinogenesis bioassay for whole-body detection of chemopreventive agents: modifying potential of S-methyl-cysteine. Cancer Lett. 206: 15-26. 2004. [Medline] [CrossRef]
13. Wei M, Arnold L, Cano M, and Cohen SM. Effects of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium. Toxicol Sci. 83: 237-245. 2005. [Medline] [CrossRef]
14. Wei M, Hamoud AS, Yamaguchi T, Kakehashi A, Morimu-ra K, Doi K, Kushida M, Kitano M, Wanibuchi H, and Fukushima S. Potassium bromate enhances N-ethyl-N-hydroxyethylnitrosamine-induced kidney carcinogenesis only at high doses in Wistar rats: indication of the existence of an enhancement threshold. Toxicol Pathol. 37: 983-991. 2009. [Medline] [CrossRef]
15. Huang XF, and Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev. 10: 610-616. 2009. [Medline] [CrossRef]
16. Corpet DE, Jacquinet C, Peiffer G, and Tache S. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr Cancer. 27: 316-320. 1997. [Medline] [CrossRef]
17. Tran TT, Medline A, and Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev. 5: 1013-1015. 1996. [Medline]
18. Boni-Schnetzler M, Schmid C, Meier PJ, and Froesch ER. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol. 260: E846-E851. 1991. [Medline]
19. Garofalo C, and Surmacz E. Leptin and cancer. J Cell Physiol. 207: 12-22. 2006. [Medline] [CrossRef]
20. Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, Kaaks R, and Olsson T. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep. 10: 2015-2021. 2003. [Medline]
21. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, Yang X, and Tian B. Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine. 26: 19-24. 2005. [Medline] [CrossRef]
22. Barb D, Williams CJ, Neuwirth AK, and Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 86: s858-s866. 2007. [Medline]
23. Wei EK, Giovannucci E, Fuchs CS, Willett WC, and Man-tzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 97: 1688-1694. 2005. [Medline] [CrossRef]
24. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, and Hankinson SE. Plasma adiponec-tin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 92: 1510-1516. 2007. [Medline] [CrossRef]
25. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 296: 1655-1657. 2002. [Medline] [CrossRef]
26. Knowles MA, Platt FM, Ross RL, and Hurst CD. Phospha-tidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 28: 305-316. 2009. [Medline] [CrossRef]
27. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, and Phillips WA. The phospha-tidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61: 7426-7429. 2001. [Medline]
28. Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, Perng LI, Wang JC, Tsai M, and Chang CP. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. Cancer Invest. 18: 123-129. 2000. [Medline] [CrossRef]
29. Vivanco I, and Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2: 489-501. 2002. [Medline] [CrossRef]
30. Chen C, Chang YC, Liu CL, Chang KJ, and Guo IC. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/ CIP1. Breast Cancer Res Treat. 98: 121-132. 2006. [Medline] [CrossRef]
31. Mistry T, Digby JE, Desai KM, and Randeva HS. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int. 101: 1317-1322. 2008. [Medline] [CrossRef]
32. Hall GC, Roberts CM, Boulis M, Mo J, and MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 28: 590-594. 2005. [Medline] [CrossRef]